Lafayette, CA, United States of America

Yi-Qing Zhou


Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 60(Granted Patents)


Company Filing History:


Years Active: 2005-2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Yi-Qing Zhou

Introduction

Yi-Qing Zhou is a prominent inventor based in Lafayette, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of benzoquinone ansamycin analogs. With a total of 2 patents, her work is paving the way for new therapeutic options in combating diseases characterized by undesired cellular proliferation.

Latest Patents

Yi-Qing Zhou's latest patents focus on benzoquinone ansamycins. These inventions relate to benzoquinone ansamycin analogs that are useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. The therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are particularly promising for treating both cancerous and non-cancerous disease conditions.

Career Highlights

Yi-Qing Zhou is currently associated with Kosan Biosciences Incorporated, where she continues to advance her research in the field of oncology. Her work has garnered attention for its potential impact on cancer therapies and the broader medical community.

Collaborations

Some of her notable coworkers include Daniel V Santi and David C Myles, who have collaborated with her on various projects aimed at enhancing the efficacy of cancer treatments.

Conclusion

Yi-Qing Zhou's innovative work in developing benzoquinone ansamycin analogs represents a significant advancement in cancer treatment. Her contributions are vital to the ongoing efforts to find effective therapies for diseases characterized by cellular proliferation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…